URGN - CIK 0001668243
UroGen Pharma Ltd. (URGN) reported revenue of $109.79M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $109.79M | +21.4% |
| FY 2024 | $90.40M | +9.3% |
| FY 2023 | $82.71M | +28.5% |
| FY 2022 | $64.36M | +34.0% |
| FY 2021 | $48.04M | +307.2% |
| FY 2020 | $11.80M | +65450.0% |
| FY 2019 | $18.00K | -98.4% |
| FY 2018 | $1.13M | -86.2% |
| FY 2017 |
UroGen Pharma Ltd. (URGN) reported revenue of $109.79M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2016 and fiscal 2025, UroGen Pharma Ltd.'s revenue grew from $17.53M to $109.79M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $8.16M |
| -53.5% |
| FY 2016 | $17.53M | - |